Article thumbnail
Location of Repository

A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer

By Naofumi Narita, Takeshi Yuasa, Norihiko Tsuchiya, Teruaki Kumazawa, Shintaro Narita, Takamitsu Inoue, Zhiyong Ma, Mitsuru Saito, Yohei Horikawa, Shigeru Satoh, Osamu Ogawa and Tomonori Habuchi
Topics: Research Article
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2006). A: TNFRSF11B gene variants and bone mineral density in postmenopausal women in Malta. Maturitas
  2. against Cancer: From Prostate. In TNM classification of malignant tumors 6th edition. Edited by: Sobin LH, Wittekind C.
  3. (2003). Austrian Group on Normative Values of Bone Metabolism: Serum levels of osteoprotegerin increase with age in healthy adult population. Bone
  4. (2003). BP: Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice.
  5. (2004). Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA
  6. (2004). Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications.
  7. (2002). CR: Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res
  8. (2001). E: Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res
  9. Ed: Prostate Cancer.
  10. (2006). Egashira T: Association between osteoprotegerin gene polymorphism and coronary artery disease in Japanese men. Atherosclerosis
  11. (2002). Eriksen EF: Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures.
  12. (2001). ET: Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone.
  13. From Histological grading and clinical staging of prostate carcinoma.
  14. (2006). Habuchi T: Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer.
  15. (2004). Hamdy FC: Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. Prostate
  16. (2002). Hata A: Linkage and association analyses of the osteoprotegerin gene locus with human osteoporosis.
  17. (1998). Higashio K: Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor.
  18. (2004). JR: Osteoprotegerin gene polymorphisms in men with coronary artery disease.
  19. (2002). Kindmark A: A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and function. Biochem Biophys Res Commun
  20. (2004). Mechanisms of bone metastasis.
  21. (2004). Redini F: RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta
  22. (2007). RL: No associations between OPG gene polymorphisms or serum levels and measures of osteoporosis in elderly Australian women. Bone
  23. (2005). RL: Osteoprotegerin in prostate cancer bone metastasis. Cancer Res
  24. (2002). Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis.
  25. (2005). Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporos Int
  26. (2003). Shimokata H: Association of polymorphisms of the osteoprotegerin gene with bone mineral density in Japanese women but not men. Mol Genet Metab
  27. The distribution of secondary growths in cancer of the breast.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.